Annual Survival Rate Statistics Update—Multiple Myeloma Rate Unchanged
New observational data from the United States National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) shows that the survival…
Patient Power: How Can Myeloma Patients Combat Neuropathy?
How can myeloma patients combat the pain and numbness caused by neuropathy? Are there alternative treatment regimens? Patient Power meets…
Our Next Show: Quad Treatment with Transplant for Newly Diagnosed Myeloma with Luciano Costa, MD, PhD University of Alabama
Monday, April 16, 2018 @ 10 am Pacific, 11 am Mountain, Noon Central, 1:00 pm Eastern Call In by Phone…
Full Show: NAM-Natural Killer Cells with Elotuzumab by Viktoria Bachanova, MD, PhD, University of Minnesota
Viktoria Bachanova, MD, PhD University of Minnesota Interview Date: March 12, 2018 Summary Natural killer cells are the body’s way…
Our Next Show: Quad Treatment with Transplant for Newly Diagnosed Myeloma with Luciano Costa, MD, PhD University of Alabama
Monday, April 16, 2018 @ 10 am Pacific, 11 am Mountain, Noon Central, 1:00 pm Eastern Call In by Phone…
Clinical Trial: BCMA CAR-T Plus LY3039478 Inhibitor in Multiple Myeloma
The use of CAR-T cell therapy is expanding in the treatment of multiple myeloma. Currently, several centers are producing their…
Upcoming Myeloma Crowd Roundtables
Upcoming Myeloma Crowd Events
We Did it! Together, Patients and Experts Helped the Myeloma Crowd Research Initiative Exceed Our $500,000 Goal for High Risk Myeloma Research
In 2015 the Myeloma Crowd had a hypothesis: If patients collaborated with myeloma experts, we could accelerate a cure. Our…
Continuing the Fight for a Myeloma Cure: Dr. Tricot and Dr. Zhan’s Research to Improve Outcomes for High-Risk Myeloma Patients
Guido Tricot, MD, PhD has devotedly attended to thousands of multiple myeloma patients for over two decades. His tandem autologous…
Thanks to our site sponsors:
